The market pendulum is swinging from one side to the other, making it difficult to predict its trajectory from one session to the next. However, in the all or nothing world of biotechs, some things will always remain the same. Case in point: Marinus Pharmaceuticals (MRNS) shares surged nearly 50% in Tuesday’s trading session, following the release of positive clinical trial data.
On Monday evening, Marinus announced that in the phase 3 clinical trial of oral ganaxolone for the treatment of CDD (CDKL5 deficiency disorder) – a rare inherited type of epilepsy with treatment-resistant seizures – the study achieved the primary endpoint by showing a statistically meaningful 32.2% reduction from baseline in median 28-day motor seizure frequency compared to the 4% placebo reduction. Safety wise, the